[EN] IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
申请人:LYSOSOMAL THERAPEUTICS INC
公开号:WO2017176961A1
公开(公告)日:2017-10-12
The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.
The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.
Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
[EN] PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
申请人:LYSOSOMAL THERAPEUTICS INC
公开号:WO2017176962A1
公开(公告)日:2017-10-12
The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-pyrrolo[1,2-a]pyrimidine-8-carboxarnide compounds and variants thereof.
Reactions of cyclic β-alkoxyvinyl α-keto esters with heteroaromatic NCC-binucleophiles
作者:Oleksandr O. Stepaniuk、Bohdan V. Vashchenko、Vitalii O. Matvienko、Ivan S. Kondratov、Andrey A. Tolmachev、Oleksandr O. Grygorenko
DOI:10.1007/s10593-020-02670-z
日期:2020.3
Reactions of five- and six-membered cyclic β-alkoxyvinyl α-keto esters and NCC-binucleophiles are described. The following binucleophiles were studied: heteroaromatic amines (pyrazoles, isoxazole, uracils, and isoquinolinone) and 2-(benzimidazolyl)acetonitrile. It was found that condensation proceeded regioselectively in the case of five-membered cyclic enone. Fused α-pyridine carboxylates, likely